Composition for improving brain function

A composition with the pentapeptide Val-Tyr-Thr-Pro-Gly addresses the lack of effective brain function improvement by enhancing cognitive function and treating dementia through chemical synthesis or rice bran-derived formulations.

JP7578424B2Active Publication Date: 2024-11-06SUNSTAR INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020110804
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-06-26
Publication Date
2024-11-06
Estimated Expiration
2040-06-26

AI Technical Summary

Technical Problem

Existing compositions do not effectively improve brain function, particularly cognitive function, despite the known physiological effects of specific peptides like Val-Tyr-Thr-Pro-Gly.

Method used

A composition containing the pentapeptide Val-Tyr-Thr-Pro-Gly (VYTPG peptide) is developed, which can be synthesized chemically or derived from rice bran using thermolysin treatment, and formulated into food or pharmaceutical products to enhance brain function.

Benefits of technology

The VYTPG peptide exhibits excellent brain function-improving effects, particularly in cognitive disorders such as memory and attention deficits, and is effective in treating and preventing dementia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578424000001
    Figure 0007578424000001
  • Figure 0007578424000002
    Figure 0007578424000002
  • Figure 0007578424000003
    Figure 0007578424000003
Patent Text Reader

Abstract

To provide a composition for improving brain functions that has excellent action of improving brain functions.SOLUTION: A composition for improving brain functions contains pentapeptide (Val-Tyr-Thr-Pro-Gly). The brain function improvement may be cognitive function improvement.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for improving brain function, which contains a specific peptide as an active ingredient. [Background technology]

[0002] It is known that peptides consisting of specific sequences exert various functions when orally ingested. For example, as disclosed in Patent Document 1, it is known that a pentapeptide consisting of Val-Tyr-Thr-Pro-Gly has various physiological actions. Patent Document 1 discloses a composition containing the pentapeptide consisting of Val-Tyr-Thr-Pro-Gly, which is for improving sugar metabolism, suppressing blood glucose level rise, and for antidiabetic purposes. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2020-2018 A Summary of the Invention [Problem to be solved by the invention]

[0004] An object of the present invention is to provide a composition for improving brain function that has an excellent effect of improving brain function. [Means for solving the problem]

[0005] The present inventors conducted research to solve the above problems and discovered that a pentapeptide consisting of sequence number 1 exhibits an excellent effect of improving brain function. In order to achieve the above-mentioned object, a composition for improving brain function according to one embodiment of the present invention is characterized by containing a pentapeptide consisting of SEQ ID NO:1.

[0006] In the composition for improving brain function, the improvement of brain function may be improvement of cognitive function. The composition for improving brain function may be an oral composition. A food composition or pharmaceutical composition in another embodiment of the present invention is characterized by comprising the above-mentioned composition for improving brain function. Effect of the Invention

[0007] According to the present invention, an excellent effect of improving brain function can be exhibited. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] Hereinafter, one embodiment of the composition for improving brain function (hereinafter also referred to as the composition) of the present invention will be described. The composition included in this embodiment contains a specific pentapeptide (SEQ ID NO: 1: Val-Tyr-Thr-Pro-Gly). In addition, in this specification, the pentapeptide consisting of the amino acid sequence: Val-Tyr-Thr-Pro-Gly may be referred to as "VYTPG peptide".

[0009] The VYTPG peptide can be prepared by chemical synthesis using known peptide synthesis methods. Examples of peptide synthesis methods include the azide method, the acid chloride method, the acid anhydride method, the mixed acid anhydride method, the DDC method, the active ester method, the carboimidazole method, and the oxidation-reduction method. These peptide synthesis methods can be performed by either solid-phase synthesis or liquid-phase synthesis.

[0010] In the above-mentioned peptide synthesis method, it is preferable to protect the amino group, carboxy group, and / or side chain functional group (e.g., the guanidino group of arginine (Arg)) with a protecting group. The protecting group is not particularly limited and any known protecting group can be used, for example, benzyloxycarbonyl group (Cbz), tert-butoxycarbonyl group (Boc), fluorenylmethoxycarbonyl group (Fmoc), benzyl group (Bz), p-toluenesulfonyl group (p-Ts), etc.

[0011] In addition, after synthesizing the VYTPG peptide by the above-mentioned peptide synthesis method, if necessary, the peptide can be purified by a known method and used as the VYTPG peptide. Furthermore, the VYTPG peptide may be obtained by hydrolyzing a protein with a protease or the like, followed by purification or crude purification. The VYTPG peptide may also be produced, for example, by treating rice bran with thermolysin. In other words, a composition obtained by treating rice bran with thermolysin (rice bran thermolysin-treated composition) contains the VYTPG peptide. Thus, the rice bran thermolysin-treated composition may be purified or crudely purified by, for example, HPLC to obtain the VYTPG peptide. Alternatively, the rice bran thermolysin-treated composition may be used as a raw material that has been treated to increase the concentration of the VYTPG peptide.

[0012] In addition, when subjecting rice bran to the thermolysin treatment, the rice bran used is not particularly limited, but is preferably defatted rice bran. In addition, defatted rice bran defatted by pressing (pressed defatted rice bran) is preferable. In particular, pressed defatted rice bran obtained by heating rice bran (raw rice bran) obtained after polishing to inactivate lipase and further performing a pressing process is preferable. In addition, it is preferable to use defatted rice bran with a lipid content of 5 to 20 mass%. Defatted rice bran with a lipid content in this range is preferably obtained by pressing defatting (particularly pressing defatting after lipase inactivation treatment).

[0013] The lipase inactivation treatment is carried out for the purpose of preventing oxidation deterioration of rice bran (raw rice bran) containing about 18 to 20% by mass of lipids. Usually, the raw rice bran is heated and roasted at about 70 to 130°C. The pressing treatment is carried out by a known pressing method, for example, pressing the rice bran that has been heated and roasted to about 100 to 115°C with a low-temperature continuous press (for example, the Miracle Chamber sold by Technosigma Co., Ltd.). It is preferable to press until the lipid content in the defatted rice bran after pressing is about 5 to 20% by mass. In addition, a drying treatment may be carried out for the purpose of reducing the moisture content of the rice bran before the lipase inactivation treatment and the defatted rice bran after oil extraction. Furthermore, it is preferable that the defatted rice bran obtained by the pressing treatment is further crushed and classified by a known method to be made into a powder form. In this case, the average particle size of the powder is preferably 5 to 200 μm, more preferably 10 to 150 μm, and most preferably 40 to 100 μm. As described above, the lipid content in the defatted rice bran is preferably 5 to 20 mass %, more preferably 7 to 15 mass %. The above-mentioned commercially available defatted rice bran can also be purchased and used. An example of such commercially available defatted rice bran is Hybref (manufactured by Sunbran Co., Ltd.).

[0014] Thermolysin used in the present invention is a known enzyme, and its EC number is 3.4.24.27. Thermolysin can be used, for example, by purchasing a commercially available product. For example, it can be purchased from Peptide Institute Co., Ltd. (Thermolysin) or Amano Enzyme Co., Ltd. (Thermoase).

[0015] The thermolysin treatment conditions for obtaining a rice bran thermolysin-treated composition are not particularly limited as long as the activity of thermolysin can be obtained, and can be set appropriately. For example, rice bran and thermolysin can be mixed in water, and reacted for about 10 to 30 hours with gentle stirring at about 37°C. After the treatment, thermolysin may be inactivated. The inactivation treatment of thermolysin can be performed, for example, by heating (for example, treatment at 100°C for about 10 to 20 minutes). After the treatment, purification may be performed, for example, by filtering and recovering the filtrate.

[0016] The concentration of VYTPG peptide can be increased or purified using the rice bran thermolysin-treated composition as a raw material by known methods such as HPLC. The composition containing VYTPG peptide exerts an excellent brain function improving effect, particularly when taken orally. The composition of the present embodiment is applied to improve brain dysfunction, particularly cognitive disorders such as memory disorder, attention disorder, executive dysfunction, and social behavior disorder. Specifically, it is used for treating, improving, and preventing dementia that develops cognitive disorders.

[0017] Specific examples of dementia include Alzheimer's disease, vascular dementia, Lewy body dementia, frontotemporal dementia, alcoholic dementia, etc. Improvement of dementia includes not only improvement of the core symptoms of dementia such as memory disorder, attention disorder, executive dysfunction, and social behavior disorder, but also improvement of peripheral symptoms such as delusions, depression, wandering, insomnia, hallucinations, and decreased motivation.

[0018] The application form of the composition is not particularly limited, and may be, for example, a food composition or a pharmaceutical composition. The VYTPG peptide may be used as a raw material for a food composition or a pharmaceutical composition as it is, or may be made into a product by appropriately mixing with a carrier, additive, etc. that is pharmacologically or food hygienically acceptable.

[0019] When used as a food composition, in addition to the VYTPG peptide as described above, other ingredients may be contained as necessary. The other ingredients are not particularly limited and may be appropriately selected depending on the purpose, and examples thereof include bases, carriers, additives that are acceptable from the standpoint of food hygiene, and other ingredients and materials that can be used as foods.

[0020] When used as a food composition, the intake form is oral intake. In this case, the form of the composition of this embodiment is not particularly limited, and can be used as general food, health functional food, or special purpose food. For example, specific health food, nutritional functional food, functional food, food for sick people, food for people with swallowing difficulties, dietary supplements, nutritional supplements, hospital food, nursing food, processed food, beverages, etc. can be mentioned. These can be prepared by ordinary methods. When the use is indicated in the food composition, indications stipulated by various laws, enforcement regulations, guidelines, etc. can be mentioned. The indication of use includes indication on packages such as packaging and containers, as well as indication on advertising media such as pamphlets.

[0021] The contents of the display of the use of the composition of this embodiment include, in addition to the display of improvement or prevention of brain function, the display of improvement or prevention of the above-mentioned core symptoms and peripheral symptoms. Also included are displays suggesting these improvements or preventions. For example, displays of maintaining, supporting, or improving memory, attention, judgment, and spatial recognition, which are part of cognitive function, can be exemplified. More specifically, expressions such as maintaining or supporting the ability to remember and recall information about things seen and heard, such as words, numbers, figures, colors, position information, and faces, helping to remember information or improving accuracy, maintaining or supporting short-term memory (the ability to retain information in a short time and process it at the same time), maintaining attention (speed and accuracy of clerical work), and maintaining the efficiency of calculation work can be exemplified.

[0022] In addition, the dosage form of the food composition may be, for example, a hard capsule, a soft capsule, a supplement, a chewable tablet, a beverage, a powdered beverage, a granule, a film, etc., or, when used as a food or drink, for example, a beverage such as a tea-based beverage, a sports beverage, a beauty beverage, a fruit juice beverage, a carbonated beverage, an alcoholic beverage, a soft drink, a jelly beverage, a concentrated type beverage diluted with water, hot water, carbonated water, etc., a powder or granule dissolved or suspended in water or hot water, etc., a dry solid such as a tablet, a tablet confectionery, a jelly, a snack, a baked confectionery, a fried confectionery, a cake, a chocolate, a gum, a candy, a gummy, etc., a soup, a noodle, a rice, a cereal, etc. Among these, in normal life, a supplement type, a chewable tablet, a one-shot drink type, etc. are preferable, and when taken for the purpose of enhancing the effect of exercise, a beverage such as a sports drink is also preferable. In particular, when the product is intended as a health functional food, dietary supplement, or nutritional supplement, it is preferable that the product be in the form of, for example, a powder, granules, paste, capsule, tablet or pill (including chewable tablets), beverage (drink powder, drink, etc.), jelly, etc., in order to facilitate continuous intake.

[0023] When the composition is used as a food additive composition or a food ingredient composition, the form is not particularly limited, and examples thereof include liquid, powder, flake, granule, and paste. More specifically, examples thereof include seasonings (sweeteners, salt substitute compositions, soy sauce, vinegar, miso, sauces, ketchup, dressings, spices, herbs, flakes (furikake, rice cooking additives, etc.), barbecue sauce, roux paste (curry roux paste, etc.)), and food premixes.

[0024] When the composition is used as a food composition, the amount of VYTPG peptide in the food composition is not particularly limited as long as the above-mentioned effects of VYTPG peptide are exerted, and can be set appropriately.

[0025] In addition, when the composition of the present invention is used as a food composition, the intake amount, intake interval, intake subject, etc. are not particularly limited and can be set appropriately. For example, the intake amount can be set appropriately depending on the age, sex, weight, health condition, and other conditions of the intake subject. For example, the intake interval, when the above-mentioned amount is taken, may be once or multiple times a day (preferably 2 to 3 times), or once or multiple times every few days to weeks. In addition, the intake subject may be a human being, or a domestic animal such as a pet or livestock, for example, a dog, a cat, a cow, a horse, a sheep, a llama, a rat, a mouse, etc.

[0026] In particular, when the subject of administration is a human, the VYTPG peptide administration (ingestion) amount is, for example, preferably about 10 to 5000 μg, more preferably about 100 to 4000 μg per day for an adult (60 kg). The administration (ingestion) period is not particularly limited, but may be, for example, 3 days to 12 weeks, or may be longer.

[0027] There are no particular limitations on the human subject to intake, but it is preferable for the human subject to intake to be a human who has a desire or need for improvement or prevention of brain function. When the subject of intake is a domestic animal, the form, intake amount, intake interval, etc. can be appropriately determined with reference to the case when the subject of intake is a human.

[0028] Pharmaceutical compositions include pharmaceuticals and quasi-drugs. When the composition of the present embodiment is used as a pharmaceutical composition, the administration method is not particularly limited, and it is possible to adopt oral administration (oral ingestion), enteral administration, intravascular administration (particularly intravenous injection), etc. When applied as a pharmaceutical composition, in addition to the VYTPG peptide as described above, other components may be included as necessary. The other components are not particularly limited and can be appropriately selected depending on the purpose, and examples thereof include pharma- ceutically acceptable bases, carriers, and / or additives (e.g., solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, etc.). The blending amount of the other components can be appropriately set depending on the purpose.

[0029] The dosage form of the pharmaceutical composition is not particularly limited, and examples thereof include tablets such as orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, and dissolving tablets; troches; powders; suspensions; emulsions; elixirs; lemonades; syrups; lotions; granules; capsules such as hard capsules and soft capsules; creams; ointments; suppositories; poultices, tapes, microneedles, transdermal / mucosal administration agents such as iontophoresis and electroporation; aerosols, etc. These forms can be prepared by combining the VYTPG peptide with other components as necessary as described above in a conventional manner.

[0030] The amount of VYTPG peptide contained in the pharmaceutical composition is not particularly limited as long as the above-mentioned action of VYTPG peptide is exerted, and can be set appropriately. When used as a pharmaceutical composition, the dosage, administration interval, administration subject, etc. are not particularly limited and can be set appropriately. For example, the dosage can be set appropriately depending on the age, sex, weight, health condition, and other conditions of the administration subject. For example, the administration interval may be once or multiple times a day (preferably 2 to 3 times), or once or multiple times every few days to weeks. In addition, the administration subject may be a human being, or a domestic animal such as a pet or livestock, for example, a dog, a cat, a cow, a horse, a sheep, a llama, a rat, a mouse, etc.

[0031] In particular, when the subject of administration is a human, the VYTPG peptide administration (ingestion) amount is, for example, preferably about 10 to 5000 μg, more preferably about 100 to 4000 μg per day for an adult (60 kg). The administration (ingestion) period is not particularly limited, but may be, for example, 3 days to 12 weeks, or may be longer.

[0032] When the subject of administration is a domestic animal, the administration form, dosage form, dosage amount, administration interval, etc. can be appropriately determined with reference to the case where the subject of administration is a human. The effects of the composition for improving brain function of this embodiment will be described.

[0033] (1) In this embodiment, the composition contains VYTPG peptide. Therefore, it can exert an excellent effect of improving brain function. In particular, it exerts an excellent effect on improving cognitive function. Furthermore, in the case of cognitive function decline caused by lifestyle habits such as a high-fat diet, short-term intake can contribute to recovery of cognitive function.

[0034] The above embodiment may be modified as follows. The composition of the above embodiment may be administered to patients for the purpose of improving symptoms related to brain function, or may be ingested by healthy individuals for the purpose of preventing the worsening of symptoms, delaying the decline of symptoms, and preventing the decline of brain function.

[0035] In the composition of the above embodiment, the amount of VYTPG peptide contained in the food composition or pharmaceutical composition is not particularly limited as long as the effects of the present invention can be obtained, and the amount can be, for example, 0.1 to 100% by mass, preferably 1 to 90% by mass, of the solid content.

[0036] In addition, in this specification, the term "comprising" includes "consisting essentially of" and "consisting of." In addition, the present invention includes all arbitrary combinations of the constituent elements described in this specification.

[0037] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present invention above may be combined in any way to specify the subject matter included in the present invention. In other words, the present invention includes all subject matter consisting of all combinations of the combinable characteristics described in this specification. EXAMPLES

[0038] The above-mentioned embodiment will be described in more detail below with reference to test examples, but the present invention is not limited thereto. (Synthesis of VYTPG peptide) Production Example 1: Synthesis of pentapeptide by Fmoc method The pentapeptide Val-Tyr-Thr-Pro-Gly was synthesized by solid phase synthesis using the Fmoc method. The resulting VYTPG peptide was purified by HPLC and sequenced using a protein sequencer, confirming that it was a pentapeptide Val-Tyr-Thr-Pro-Gly.

[0039] Production Example 2: Synthesis of pentapeptide by the Boc method We requested the synthesis of a pentapeptide consisting of Val-Tyr-Thr-Pro-Gly by the Boc method from Peptide Institute, Inc. The delivered VYTPG peptide was confirmed to be a pentapeptide consisting of Val-Tyr-Thr-Pro-Gly by RP-HPLC, mass spectrometry and amino acid analysis.

[0040] Production Example 3: Purification of pentapeptide from enzymatically treated rice bran First, rice bran was enzymatically treated to obtain an enzymatically treated composition as described below. Thermolysin (Peptide Institute, Inc.; Code 3504) was used as the enzyme.

[0041] The rice bran used was Hybref (manufactured by Sunbran Co., Ltd.). Hybref is pressed defatted rice bran that has been defatted by squeezing rice bran. First, rice bran was mixed with ultrapure water to a concentration of 30 g / L, and thermolysin was added to the mixture to a concentration of 0.4 g / L. The mixture was then incubated in a 37°C incubator for 20 hours while stirring at 250 rpm using a stirrer. The mixture was then immersed in a boiling water bath for 15 minutes to inactivate the enzyme. The mixture was centrifuged at 15°C and 7150 rpm (8000 x g) for 15 minutes, and the pH of the resulting supernatant was adjusted to 7.0 using NaOH, filtered using filter paper No. 2 (manufactured by Advantec), and the resulting filtrate was freeze-dried. The freeze-dried product was used as a rice bran enzyme-treated composition. The rice bran enzyme-treated composition may be hereinafter referred to as "HB-T".

[0042] Next, the VYTPG peptide was purified from HB-T as follows. The HB-T aqueous solution, adjusted to 50 mg / mL with ultrapure water, was fractionated using a preparative HPLC system (1525 binary pump, 2487 spectrometer). A C18 (Cosmosil 5C18-AR-II 4.6 x 250 mm) column was used. The HPLC conditions were as shown in Table 1 below.

[0043] [Table 1] Peak 53 in the obtained HPLC chart was fractionated, concentrated, centrifuged, and dissolved in 400 μL of ultrapure water. 100 μL of this was fractionated under the analytical HPLC conditions shown in Table 2 below. A PE column (Cosmosil 5PE-MS 4.6 × 250 mm) was used.

[0044] [Table 2] Peak 53-13 in the obtained chart was collected, concentrated, centrifuged, and dissolved in 100 μL of ultrapure water. The sample was again fractionated by analytical HPL. The injection volume was 50 μL, and a CN column (Cosmosil 5CN-MS 4.6 × 250 mm) was used. Peak 533 in the obtained chart was purified. The obtained purified sample was analyzed by a mass spectrometer and a protein sequencer, and was found to be VYTPG peptide.

[0045] (Measurement of cognitive function) The test method was based on the mouse object recognition test method (Marianne. Leger et al., Nature Protocols 8 (12), 2531-2537, 2013).

[0046] The mice used in the study were 11-week-old male ddY mice. They were fed a high-fat diet for one week to acclimate them, and then divided into two groups. Both groups were kept on a high-fat diet for one week (free food and water intake). One group (VYTPG peptide group) was orally administered 1 mg / kg of VYTPG peptide prepared in saline using a Teflon tube, and the other control group was orally administered the same amount of saline on the 5th, 6th, and 7th days of the week.

[0047] The high-fat diet used was HFD-60 (manufactured by Oriental Bio Co., Ltd.) consisting of the ingredients shown in Table 3.

[0048] [Table 3] On the sixth day of rearing, one mouse from each group was placed in a box of a given size and allowed to acclimate to the environment for five minutes (acclimatization 1). 24 hours later, the mouse was placed in a box with two substances, one on each side, and allowed to move around until the total exploration time for both substances reached 20 seconds, after which it was removed from the box and returned to its cage (acclimatization 2). At this time, both substances in the box were the same, either building blocks or flasks. Another hour later, the mouse was placed in a box in which one of the two substances had been replaced with a substance of a different shape, and allowed to move around until the total exploration time for both substances reached 20 seconds, and the percentage (%) of the time spent exploring the new substance that had been replaced was calculated.

[0049] In addition, the test was conducted in a completely random manner, so that the novel substance was placed on the right side or the left side. The test box was placed in an area separated by a partition, and the tester observed the behavior of the mouse from outside the partition through a video camera installed above the box, so that the mouse could not see it. All of the tests were conducted in a facility set at 23°C with a 12-hour light and 12-hour dark cycle.

[0050] The average value ± standard deviation was calculated for each test group. The results for each group are shown in Table 4. There was no significant difference in body weight between the groups during the test period. * indicates vs. Control: p<0.05 (Tukey's multiple test).

[0051] [Table 4] As shown in Table 4, the group of individuals to which VYTPG peptide was added in a high-fat diet showed a significantly increased proportion of time spent exploring novel substances compared to the control group.

Claims

1. A composition for improving brain function comprising a pentapeptide consisting of SEQ ID NO: 1, The composition for improving brain function, wherein the improvement of brain function is improvement of cognitive function.

2. The composition for improving brain function according to claim 1, which is an oral composition.

3. A food composition or pharmaceutical composition for improving cognitive function, comprising the composition for improving brain function according to claim 1 or 2.

Citation Information

Patent Citations

  • Pentapeptide and composition containing the peptide

    JP2020002018A

  • Composition for improving brain function

    JP2020174615A

  • Composition for ameliorating obesity and composition for ameliorating type ii diabetes

    JP2021093995A